Metabolic liver disease

Determine levels of fibrosis and necroinflammatory activity

Our robust menu of biomarker testing assesses liver disease related to nonalcoholic and alcoholic causes. These include FibroTest-ActiTest, a first-line screening assay that uses two diagnostic scores based on component tests for six biomarkers to assess the liver for nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH)-FibroTest, which evaluates 10 biomarkers to assess liver condition; and direct alcohol biomarker testing, which assesses the blood for alcohol use.

Metabolic liver disease Test menu

FibroTest-ActiTest

FibroTest-ActiTest assesses the liver for fibrosis and inflammation using two diagnostic scores based on component testing of six biomarkers. It is the most reliable biomarker test available, applies to the largest number of patients (98%),4 and outperforms other testing at all stages of fibrosis.5

Key testing

Advantages

  • Noninvasive testing is minimally affected by known risk factors for false positives and false negatives.6
  • Easy-to-read report shows both proprietary FibroTest and ActiTest scores and METAVIR fibrosis stage and activity grade.

Highlights


NASH, steatosis, and fibrosis/cirrhosis testing

Using a simple blood sample, our nonalcoholic steatohepatitis FibroTest combines 10 standard biomarkers into five scores to provide a complete assessment of the liver condition and the five main causes of liver disease, including hepatic steatosis, NASH, alcoholic steatohepatitis, fibrosis, and liver inflammation.

Key testing

Advantages

  • Confirms diagnosis and monitoring of liver fibrosis, steatosis, and inflammation.
  • Useful for estimating hepatic fibrosis.
  • Assesses inflammation of metabolic disease.
  • Assesses severity of NASH in patients with NAFLD, as well as steatosis or fatty liver.

Alcoholic liver disease confirmation and monitoring

Diagnosing individuals with alcoholic liver disease, which encompasses a spectrum of liver injury, often requires a history of significant alcohol intake, clinical evidence of liver disease, and supporting laboratory testing.7 Our menu of direct ethanol biomarker testing accurately assesses alcohol use and includes direct biomarker testing, which enables detection of even small amounts of ethanol eliminated via non-oxidative pathways into ethyl glucuronide (EtG), ethyl sulfate (EtS), and phosphatidylethanol (PEth).8

Benefits of biomarker testing include improved analysis of the specific role alcohol plays in an individual’s health; clarity on the actual amounts of recent consumption, which, combined with questionnaires, can support initiating clinical interventions; and verification and monitoring of ethanol abstinence in liver transplant candidates/patients.

Key testing

Highlights


References
  1. Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017 Dec;23(47):8263-8276.
  2. CDC estimates nearly 2.4 million Americans living with hepatitis C. Available from: https://www.cdc.gov/hepatitis/statistics/2022surveillance/hepatitis-c/figure-3.1.htm
  3. Marengo A, Jouness RIK, Bugianesi E. Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis. 2016;20(2):G313–G324. doi:10.1016/j.cld.2015.10.010
  4. Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol. 2011;11:39. doi:10.1186/1471-230X-11-39  
  5. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 2016;43:1.
  6. Poynard T, de Ledinghen V, Zarski JP, et al. Performances of Elasto-FibroTest,® a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2012;36(5):455-63.
  7. O'Shea, RS, Dasarathy, S, McCullough, AJ. Alcoholic liver disease. Hepatology. 51:307-328. https://doi.org/10.1002/hep.23258
  8. Chaudhari R, Moonka D, Nunes F. Using biomarkers to quantify problematic alcohol use. J Fam Pract. 2021 Dec;70(10):474-481. doi:10.12788/jfp.0317
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.